You’re cruising through a neuro q-bank when a stem hits you with optic neuritis + myelitis and suddenly every demyelinating disease you’ve ever learned shows up in your brain at once. This is exactly where Neuromyelitis Optica (NMO, Devic disease) lives: it looks MS-ish at first glance, but the pathophysiology, test findings, and treatment are different enough that missing the distinction can cost you points (and in real life, cost patients function).
Tag: Neurology > Neurodegenerative & Demyelinating
The Clinical Vignette (Q-Bank Style)
A 29-year-old woman presents with acute painful vision loss in her right eye and worsening leg weakness over 2 days. She reports urinary retention and a tight “band-like” sensation around her torso. Exam shows decreased visual acuity in the right eye and bilateral lower-extremity weakness with hyperreflexia. MRI spine reveals a long segment of T2 hyperintensity spanning multiple vertebral levels. CSF shows mild pleocytosis. Which of the following antibodies is most likely present?
A. Anti-aquaporin-4 (AQP4) IgG
B. Anti–myelin oligodendrocyte glycoprotein (MOG) IgG
C. Anti–acetylcholine receptor antibodies
D. Anti-Hu (ANNA-1) antibodies
E. Oligoclonal IgG bands
Correct answer: A. Anti-aquaporin-4 (AQP4) IgG
Why the Correct Answer Is Correct: NMO (Devic) in One Picture
The “classic” NMO pattern
Neuromyelitis optica is an autoimmune astrocytopathy (not a primary oligodendrocyte problem) characterized by attacks of:
- Optic neuritis (often severe, can be bilateral)
- Transverse myelitis that is typically longitudinally extensive
- LETM = spinal cord lesion extending ≥ 3 vertebral segments
What’s being targeted?
- AQP4 is a water channel on astrocyte foot processes at the blood–brain barrier.
- Anti-AQP4 IgG leads to complement-mediated injury → inflammation and secondary demyelination.
High-yield imaging clue
- Spinal cord MRI: long, central cord lesions spanning multiple segments (LETM).
MS lesions are typically shorter and more peripheral.
High-yield CSF clue
- NMO can have CSF pleocytosis and elevated protein.
- Oligoclonal bands are less common than in MS.
The Money Step: Management Differences vs MS (Testable!)
This is where boards love to trap you.
Acute attack treatment
- High-dose IV steroids (e.g., methylprednisolone)
- If refractory: plasmapheresis
Long-term relapse prevention (immunosuppression)
- Rituximab (anti-CD20), azathioprine, mycophenolate
- Also commonly tested newer agents: eculizumab (C5 inhibitor), inebilizumab, satralizumab
Crucial pitfall
Some MS disease-modifying therapies (e.g., interferon-β) may be ineffective or even worsen NMO. When the question hints “MS meds didn’t work” or “worsened,” think NMO.
Systematically Crushing the Distractors (Why Each One Is Wrong)
B. Anti-MOG IgG
Why it’s tempting: MOG-associated disease (MOGAD) can also present with optic neuritis and transverse myelitis, and it can mimic both MS and NMO.
Why it’s wrong here (most likely):
- This stem is built around classic NMO patterns (severe optic neuritis + LETM + classic board framing).
- On exams, AQP4 is the most “canonical” antibody tied to Devic/NMO.
How to separate them quickly (high yield):
- AQP4-NMO: astrocyte injury, often more severe disability, higher relapse risk.
- MOGAD: can be optic neuritis (often anterior), may have better recovery; antibody is anti-MOG.
Exam tip: If they explicitly say AQP4-negative or emphasize recurrent optic neuritis with good recovery, consider MOGAD.
C. Anti–acetylcholine receptor antibodies
What it points to: Myasthenia gravis
Why it’s wrong:
- MG causes fluctuating fatigable weakness (ptosis, diplopia, bulbar symptoms), not:
- optic neuritis (painful monocular vision loss)
- spinal cord sensory level / hyperreflexia
- urinary retention due to transverse myelitis
- MG is a neuromuscular junction problem, not CNS demyelination.
Board pearl: Reflexes are usually normal in MG; UMN signs (hyperreflexia, Babinski) argue against it.
D. Anti-Hu (ANNA-1) antibodies
What it points to: Paraneoplastic neurologic syndromes, classically with small cell lung carcinoma.
Why it’s wrong:
- Anti-Hu is linked to sensory neuronopathy, encephalomyelitis, cerebellar degeneration—typically a different clinical pattern and demographic.
- This vignette screams inflammatory demyelinating cord + optic nerve, not paraneoplastic.
High-yield association:
- Anti-Hu (ANNA-1) ↔ SCLC
- Anti-Yo ↔ breast/ovarian (cerebellar degeneration)
- Anti-Ri ↔ breast (opsoclonus-myoclonus)
E. Oligoclonal IgG bands
What it points to: Multiple sclerosis
Why it’s tempting: Optic neuritis and myelitis are both MS features.
Why it’s wrong here:
- MRI spine shows longitudinally extensive lesions (≥ 3 vertebral segments), which is much more characteristic of NMO.
- MS typically has:
- shorter spinal lesions
- brain MRI with periventricular “Dawson fingers”
- CSF oligoclonal bands commonly positive
Fast MS vs NMO table (memorize this)
| Feature | MS | NMO (Devic) |
|---|---|---|
| Key pathology | Immune-mediated demyelination | Anti-AQP4 astrocytopathy with secondary demyelination |
| Optic neuritis | Common, often unilateral, moderate | Often severe, can be bilateral |
| Myelitis | Short-segment | LETM (≥ 3 vertebral segments) |
| CSF oligoclonal bands | Common | Less common |
| First-line long-term therapy | MS DMTs (e.g., interferons, glatiramer) | Immunosuppression (rituximab, azathioprine, etc.) |
High-Yield NMO One-Liners (USMLE Gold)
- NMO = optic neuritis + longitudinally extensive transverse myelitis + anti-AQP4 IgG
- AQP4 is on astrocytes (think “water channel” at BBB).
- Treat acute attacks with high-dose IV steroids; escalate to plasmapheresis.
- Prevent relapses with immunosuppression (rituximab, azathioprine, mycophenolate; newer biologics show up in newer resources).
- Do not assume MS when the spinal lesion is long and central—that’s a classic NMO giveaway.
Quick Practice: If the Stem Changed, Would Your Answer?
- Brain MRI shows periventricular plaques + Dawson fingers + CSF oligoclonal bands → think MS
- AQP4-negative recurrent optic neuritis with good recovery → consider MOGAD
- Fluctuating ptosis/diplopia worse at end of day → think MG
- Older smoker with subacute sensory neuropathy + SCLC history → think paraneoplastic (anti-Hu)
Frequently Asked Questions
How do you tell neuromyelitis optica from multiple sclerosis on a question stem?
Neuromyelitis optica is suggested by severe optic neuritis plus longitudinally extensive transverse myelitis, especially when spinal MRI shows a long central lesion spanning at least 3 vertebral segments. Multiple sclerosis more often has shorter, more peripheral spinal cord lesions, commonly positive CSF oligoclonal bands, and brain MRI findings such as periventricular Dawson fingers. In NMO, oligoclonal bands are less common and anti-AQP4 IgG is the classic antibody.
Why does anti-aquaporin-4 cause neuromyelitis optica?
Anti-aquaporin-4 IgG causes neuromyelitis optica because it targets aquaporin-4 water channels on astrocyte foot processes at the blood–brain barrier. This produces complement-mediated astrocyte injury, followed by inflammation and secondary demyelination. That is why NMO is considered an autoimmune astrocytopathy rather than a primary oligodendrocyte disorder.
What MRI and CSF findings point to neuromyelitis optica?
The key MRI clue is a long, central spinal cord T2 lesion extending across multiple vertebral levels, called longitudinally extensive transverse myelitis. A lesion spanning at least 3 vertebral segments is especially characteristic. CSF in NMO can show mild pleocytosis and elevated protein, while oligoclonal IgG bands are less common than they are in multiple sclerosis.
What is the treatment for an acute neuromyelitis optica attack and how is relapse prevention different from MS?
An acute neuromyelitis optica attack is treated with high-dose IV steroids, and plasmapheresis is used if the attack is refractory. Long-term relapse prevention relies on immunosuppression such as rituximab, azathioprine, mycophenolate, and commonly tested newer agents including eculizumab, inebilizumab, and satralizumab. This differs from multiple sclerosis because some MS disease-modifying therapies, including interferon-beta, may be ineffective or even worsen NMO.
How do you distinguish neuromyelitis optica from myasthenia gravis or anti-Hu paraneoplastic disease?
Neuromyelitis optica causes painful monocular vision loss and transverse myelitis findings such as hyperreflexia, urinary retention, and a sensory level, pointing to inflammatory CNS disease. Myasthenia gravis instead causes fluctuating fatigable weakness with normal reflexes and does not cause optic neuritis or spinal cord signs. Anti-Hu syndromes are linked to paraneoplastic disease, especially small cell lung carcinoma, and more often cause sensory neuronopathy, encephalomyelitis, or cerebellar degeneration rather than the classic optic neuritis plus longitudinally extensive myelitis pattern.